Alivus Life Sciences Recommends Final Dividend of ₹5/Share; Reports FY26 Audited Results
Alivus Life Sciences reported audited results for FY26. The company recommended a final dividend of ₹5 per share. The Board of Directors met on May 14, 2026, to approve the results and dividend recommendation.
The recommendation of a final dividend and the reporting of annual financial results are material information for investors, impacting investment decisions. The specific financial figures also contribute to the impact level.
The company reported its audited financial results and recommended a final dividend, which is generally viewed positively by investors.
Alivus Life Sciences Limited announced its audited financial results for the quarter and year ended March 31, 2026, following a Board of Directors meeting held on May 14, 2026. The company reported a total income of ₹711.89 crore for the quarter and ₹2,612.24 crore for the year. Expenses for the quarter stood at ₹496.09 crore, resulting in a profit before tax of ₹215.79 crore. For the full year, total expenses were ₹1,835.27 crore, with a profit before tax of ₹751.30 crore.
The Board of Directors has recommended a final equity dividend of ₹5 per equity share (250%) for the financial year 2025-26. This dividend is subject to shareholder approval at the upcoming Annual General Meeting (AGM).
The company also reported an auditor's report with an unmodified opinion on the audited financial results for the year ended March 31, 2026. A declaration from the Chief Financial Officer confirmed this unmodified opinion. The financial statements and auditor's report will be available on the company's website, www.alivus.com, in the Investors Section.
What to do with a filing like this
Alivus Life Sciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alivus Life Sciences Limited. Read the original for the full detail.